红金消结胶囊联合米非司酮治疗子宫肌瘤的疗效及对血清Ang-2、EGF、NF-κBp65水平的影响  

Efficacy of Hongjin Xiaojie Capsule and Mifepristone in the Treatment of Hysteromyoma and its Effect on the Serum Ang-2,EGF and NF-kappa Bp65 Levels

作　　者：向佳兵 高媛[1] 邱彦利 孙瑛 王树香 XIANG Jia-bing;GAO Yuan;QIU Yan-li;SUN Ying;WANG Shu-xiang(Special Diagnosis Department of 962 Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army,Harbin,Heilongjiang,150000,China;Department of Gynecology,Harbin Red Cross Central Hospital,Harbin,Heilongjiang,150000,China)

机构地区：[1]中国人民解放军联勤保障部队第九六二医院特诊科,黑龙江哈尔滨150000 [2]哈尔滨红十字中心医院妇科,黑龙江哈尔滨150000

出　　处：《现代生物医学进展》2019年第23期4500-4503,4557,共5页Progress in Modern Biomedicine

基　　金：黑龙江省自然科学基金项目(D200906).

摘　　要：目的:探讨红金消结胶囊联合米非司酮治疗子宫肌瘤的疗效及对血清血管生成素-2(Ang-2)、表皮生长因子(EGF)、核因子-κBp65(NF-κBp65)水平的影响。方法:选择我院2017年5月至2018年5月接诊的103例子宫肌瘤患者,通过随机数表法将其分为观察组53例和对照组50例。对照组给予米非司酮治疗,观察组在对照组基础上联合红金消结胶囊治疗,两组患者在月经期间停药,均连续治疗3个月。比较两组的临床疗效、治疗前后血清Ang-2、EGF、NF-κBp65、卵泡雌激素(FSH)、促黄体生成素(LH)、雌二醇(E2)水平、子宫体积与瘤体情况的变化及不良反应的发生情况。结果:治疗后,观察组临床疗效总有效率为94.34%,显著高于对照组78%,P<0.05),血清Ang-2、EGF、NF-κBp65、FSH、LH、E2水平均显著低于对照组(P<0.05),子宫体积和子宫肌瘤体积均小于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:红金消结胶囊联合米非司酮治疗子宫肌瘤的临床疗效显著优于单用米非司酮治疗,其可更显著改善患者性激素水平,缩小子宫和子宫肌瘤的体积,这可能与降低血清Ang-2、EGF、NF-κBp65水平有关。Objective:To study the efficacy of Hongjin Xiaojie Capsule and mifepristone in the treatment of hysteromyoma and its effect on the serum Ang-2,EGF and NF-kappa Bp65 levels.Methods:103 patients with hysteromyoma were selected from May 2017 to May 2018 in our hospital.They were divided into the observation group(53 cases)and the control group(50 cases)by the random number table method.The control group was treated with mifepristone,while the observation group was treated with Hongjin Xiaojie Capsule on the basis of control group.The two groups of patients stopped taking medicine during menstruation and were treated continuously for3 months.The clinical efficacy,changes of serum Ang-2,EGF,NF-kappa Bp65,uterine volume and tumors,follicular estrogen(FSH),luteinizing hormone(LH),estradiol(E2)levels and incidence of adverse reactions were compared between the two groups.Results:After treatment,the total effective rate of observation group was 94.34%,which was significantly higher than 78%in the control group(P<0.05);the serum levels of Ang-2,EGF,NF-kappa Bp65,FSH,LH and E2 were significantly lower than those of the control group(P<0.05);the uterine volume and uterine leiomyoma volume of the observation group were smaller than those of the control group(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The clinical efficacy of Hongjin Xiaojie Capsule combined with mifepristone in the treatment of uterine leiomyoma is significantly better than that of mifepristone alone.it can significantly improve the sex hormone level of patients and reduce the volume of uterine and uterine leiomyoma,which may be related to the reduction of serum Ang-2,EGF and NF-kappa B p65 levels.

关 键 词：红金消结胶囊 米非司酮 子宫肌瘤 血管生成素-2 表皮生长因子 核因子-ΚBP65 

分 类 号：R737.33[医药卫生—肿瘤]